NEW YORK (GenomeWeb News) – Response Genetics today said that its revenues in the third quarter dropped 24 percent year over year as both pharmaceutical client and ResponseDX revenues fell.

The firm's total revenues for the third quarter came in at $4.1 million, down from $5.4 million a year ago. Pharma client revenues decreased 35 percent year over year, the Los Angeles-based molecular diagnostics shop said, adding that ResponseDX revenues were down 16 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.